CATX

#3150
Perspective Therapeutics, Inc. Common Stock
3.1 5 USD
+0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.13
3.17
Jahresspanne
1.96
6.16
Tagesänderung
+1.94%
Monatliche Änderung
+8.25%
6 month change
-39.31%
Jahresänderung
-6.80%
Vorheriger Schlusskurs
3.0 9
Open
3.1 3
Tief
3.1 3
Hoch
3.1 7
Volumen
652
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Perspective Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K

Perspective Therapeutics, Inc. current report, Q2 FY2026

Full document

Business Context and Reporting Period

Perspective Therapeutics, Inc. (NYSE American: CATX) filed this Form 8-K to report the results of its 2026 Annual Meeting of Stockholders held on May 27, 2026. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation frequency.

Key Financial Metrics

This filing is a Current Report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

The filing reports the following material outcomes from the Annual Meeting:

  • Quorum: 97,882,462 shares (85.85% of outstanding shares) were represented, establishing a quorum.
  • Proposal 1 (Director Election): All six nominees were elected to the Board of Directors for a term ending at the 2027 Annual Meeting.
    • Maya Martinez-Davis and Johan (Thijs) Spoor received the highest support with over 77 million "For" votes each.
    • Frank Morich, M.D., Ph.D. received the lowest support among nominees with 62,317,819 "For" votes and 14,965,406 "Withheld" votes.
    • All nominees had 20,599,237 Broker Non-Votes.
  • Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
    • For: 97,636,978
    • Against: 125,426
    • Abstain: 120,058
  • Proposal 3 (Say-on-Pay Frequency): Stockholders voted to hold advisory votes on executive compensation annually.
    • 1 Year: 76,479,166 votes (Majority)
    • 2 Years: 274,495 votes
    • 3 Years: 364,497 votes

Guidance, Outlook, and Management Commentary

Based on the voting results, the Board intends to hold non-binding, advisory stockholder votes on executive compensation on an annual basis until the next required frequency vote or until the Board determines otherwise. The filing contains no financial guidance, risk factors, or contingencies beyond the standard governance disclosures.

Investor Verification Checklist

  • Verify the specific reasons for the higher "Withheld" vote count for nominee Frank Morich compared to other directors.
  • Confirm the Company's upcoming financial reporting schedule, as this 8-K does not contain fiscal year-end financial data.
  • Review the Company's proxy statement for the 2026 Annual Meeting for detailed biographical information on the newly elected directors.
  • Monitor future filings for the Company's 2026 Annual Report (Form 10-K) to assess financial performance and liquidity.

Nachrichten